Lisata Therapeutics, Inc. (NASDAQ:LSTA – Get Free Report) saw a large growth in short interest during the month of August. As of August 14th, there was short interest totaling 89,867 shares, a growth of 59.5% from the July 30th total of 56,341 shares. Based on an average trading volume of 78,742 shares, the short-interest ratio is presently 1.1 days. Approximately 1.1% of the shares of the stock are short sold.
Hedge Funds Weigh In On Lisata Therapeutics
Large investors have recently bought and sold shares of the stock. Cerity Partners LLC bought a new stake in Lisata Therapeutics in the second quarter valued at approximately $32,000. CIBC Bancorp USA Inc. bought a new position in shares of Lisata Therapeutics in the third quarter worth approximately $37,000. Ground Swell Capital LLC increased its stake in shares of Lisata Therapeutics by 64.0% in the fourth quarter. Ground Swell Capital LLC now owns 38,987 shares of the company’s stock worth $73,000 after buying an additional 15,213 shares during the period. Renaissance Technologies LLC raised its holdings in Lisata Therapeutics by 6.1% during the 4th quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock valued at $230,000 after buying an additional 7,093 shares during the last quarter. Finally, Deltec Asset Management LLC purchased a new stake in Lisata Therapeutics during the 1st quarter valued at $451,000. 8.94% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research analysts recently commented on the company. Zacks Research raised Lisata Therapeutics to a “hold” rating in a research note on Monday, May 18th. HC Wainwright cut Lisata Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Finally, Weiss Ratings upgraded Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Lisata Therapeutics has a consensus rating of “Reduce”.
Lisata Therapeutics Price Performance
NASDAQ LSTA traded up $0.08 during trading on Tuesday, hitting $1.57. 475,490 shares of the company’s stock traded hands, compared to its average volume of 183,784. The stock has a fifty day moving average of $2.16 and a two-hundred day moving average of $3.36. Lisata Therapeutics has a 12-month low of $0.99 and a 12-month high of $5.07. The firm has a market cap of $14.15 million, a P/E ratio of -0.96 and a beta of 0.88.
Lisata Therapeutics Company Profile
Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.
Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.
See Also
- Five stocks we like better than Lisata Therapeutics
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
